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Abstract
Introduction: The expression of proinflammatory protein tissue transglutaminase 2 (TG2) is frequently upregulated
in multiple cancer cell types. However, the exact role of TG2 in cancer cells is not well-understood. We recently
initiated studies to determine the significance of TG2 in cancer cells and observed that sustained expression of TG2
resulted in epithelial-to-mesenchymal transition (EMT) and promoted cancer stem cell (CSC) traits in mammary
epithelial cells. These results suggested that TG2 could serve as a promising therapeutic target for overcoming
chemoresistance and inhibiting metastatic spread of cancer cells.
Methods: Using various mutant constructs, we analyzed the activity of TG2 that is essential for promoting the
EMT-CSC phenotype.
Results: Our results suggest that catalytically inactive TG2 (TG2-C277S) is as effective as wild-type TG2 (TG2-WT) in
inducing the EMT-CSC in mammary epithelial cells. In contrast, overexpression of a GTP-binding-deficient mutant
(TG2-R580A) was completely incompetent in this regard. Moreover, TG2-dependent activation of the
proinflammatory transcription factor NF-B is deemed essential for promoting the EMT-CSC phenotype in
mammary epithelial cells.
Conclusions: Our results suggest that the transamidation activity of TG2 is not essential for promoting its
oncogenic functions and provide a strong rationale for developing small-molecule inhibitors to block GTP-binding
pockets of TG2. Such inhibitors may have great potential for inhibiting the TG2-regulated pathways, reversing drug
resistance and inhibiting the metastasis of cancer cells.
Introduction
Despite significant advances in early detection and treat-
ment of breast cancer, mortality due to metastatic dis-
ease remains high. A growing body of evidence supports
the notion that acquisition of epithelial-to-mesenchymal
transition (EMT) by breast cancer cells is an important
mechanism in the progression and pathogenesis of can-
cer [1,2]. EMT is a developmentally regulated process in
which adherent epithelial cells lose their epithelial char-
acteristics and acquire mesenchymal properties,
including fibroid morphology, characteristic changes in
gene expression and increased invasion and resistance
to chemotherapy [3]. In addition to eliciting the invasive
phenotype, EMT also induces cancer stem cell (CSC)-
like traits that are considered to provide cancer cells
with the ability to self-renew and colonize at metastatic
sites [4]. Thus aberrant expression of EMT regulators in
breast cancer cells may contribute to disease progres-
sion, and their identification could yield novel therapeu-
tic targets for improved patient outcomes.
In our quest to determine the significance of elevated
tissue transglutaminase 2 (TG2) expression in drug-
resistant and metastatic breast cancer cells [5,6], we
found that stable expression of TG2 in mammary
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epithelial cells is associated with EMT. TG2-induced
EMT was associated with constitutive activation of the
NF-B and increased expression of transcription repres-
sors such as Snail1, Twist1, Zeb1 and Zeb2 [7]. The
TG2-induced EMT is related to TGF-b signaling in that
cells transfected with TG2-shRNA prior to TGF-b treat-
ment failed to undergo EMT compared with control
shRNA-transfected cells, which showed morphologic
and molecular alterations typical of mesenchymal cells
in response to TGF-b treatment. Importantly, TG2-
induced EMT was associated with enrichment of the
CD44high/CD24-/low cell population, increased ability to
form mammospheres and self-renewal ability [8], traits
that are considered to endorse the CSC phenotype.
These observations revealed a novel function for TG2
and suggested that TG2-regulated pathways play an
important role in acquisition of drug resistance and
metastasis by conferring the EMT-CSC phenotype in
mammary epithelial cells.
TG2 is structurally and functionally a complex protein
that has been implicated in diverse processes such as
inflammation, wound-healing, celiac disease and cancer
[9,10]. In addition to catalyzing calcium-dependent
transamidation reactions, TG2 can bind and hydrolyze
GTP. Under physiological conditions, low calcium and
high GTP levels sustain TG2 in a latent form with
respect to transamidation activity. Under pathological
conditions, however, perturbation in calcium homeosta-
sis and decreased GTP reserves could activate TG2 to
its transamidation configuration. Researchers in several
recent studies have demonstrated increased expression
of TG2 in multiple cancer cell types [11-15]. Impor-
tantly, TG2 expression in cancer cells has been asso-
ciated with increased resistance to chemotherapy,
metastasis and poor patient outcomes [5,13,14]. Inhibi-
tion of TG2 by siRNA, antisense RNA or small-mole-
cule inhibitors reversed the sensitivity of cancer cells to
chemotherapeutic drugs and attenuated their invasion,
both in vitro and in animal models [6,12-14,16,17]. In
view of these observations, we initiated studies to deter-
mine which of the two well-characterized activities of
TG2 (protein cross-linking activity and GTP-binding
activity) is responsible for promoting the oncogenic func-
tions. Herein we provide evidence that, similar to wild-
type TG2, expression of transamidation-inactive mutants
(C277S and W241A) is able to induce EMT-CSC in
mammary epithelial cells. In contrast, the expression of
the GTP-binding-deficient TG2 mutant (R580A) failed to
induce EMT-CSC-related changes. Our current studies
suggest that cancer cells utilize the GTP-binding and
GTP-signaling function of TG2 to acquire chemoresis-
tance and the metastatic phenotype and that this infor-
mation can be exploited to develop small-molecule
inhibitors to inhibit TG2-regulated pathways and reverse
the EMT and CSC phenotypes.
Materials and methods
Materials
Immortalized human mammary epithelial cells
(MCF10A) were maintained as previously described [7].
Wild-type (WT) and mutant TG2 constructs (C277S,
W241A and R580A) were stably expressed in MCF10A
cells by retroviral transfection and selection against pur-
omycin as previously described [7]. Multiple stable
clones were used to eliminate potential clonal effects.
All experiments were performed between passages 5
and 20. Detailed procedures for lentivirus production
and infection are described in Additional file 1.
In situ transglutaminase activity and GTP-agarose pull-
down assay
In situ transglutaminase activity of different TG2 con-
structs was determined by 5-(biotinamido)pentylamine
(BPA) (Pierce Biotechnology, Rockford, IL, USA) conju-
gation to cellular proteins as previously described [11].
Briefly, cells were plated in six-well plates and incubated
with 1 mM BPA overnight, followed by 8 hours of treat-
ment with A23187 calcium ionophore (4 μM) to induce
cytosolic calcium and TG2 activation. At the end of the
incubation period, cells were lysed and equal amounts
of proteins were fractionated by SDS-PAGE. Proteins
were transferred onto nitrocellulose membranes and
probed with horseradish peroxidase-conjugated strepta-
vidin (GE Healthcare Life Sciences, Piscataway, NJ,
USA). The membranes were stripped and reprobed with
anti-TG2 mAb (CUB7401; NeoMarkers, Fremont, CA,
USA) or b-actin antibodies to establish TG2 expression
or even protein loading, respectively.
The GTP-agarose pull-down assay was performed to
check the GTP-binding ability of different TG2 con-
structs according to a procedure described previously
[18]. Briefly, cells were rinsed in ice-cold PBS and col-
lected in GTP-binding buffer (20 mM Tris·HCl, pH 7.5,
5 mM MgCl2, 2 mM phenylmethylsulfonylfluoride, 20
mg/ml leupeptin, 20 mg/ml pepstatin, 10 mg/ml aproti-
nin, 300 mM NaCl and 0.5% Triton X-100). Samples
were sonicated for 15 seconds and centrifuged (13,000 g
for 10 min) at 4°C. The supernatants were collected,
and 100 μg of lysate protein were incubated with 100 μl
of GTP-agarose beads (Sigma-Aldrich, St Louis, MO,
USA) for 30 minutes at 4°C in a 500-μl total volume of
GTP-binding buffer. The beads were centrifuged at
10,000 g for 2 minutes, and the supernatant was
retained. The beads were washed three times with 1 ml
of GTP-binding buffer, and the retained supernatant
was incubated with the beads overnight at 4°C. The
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beads were washed again as described above, and bound
proteins were eluted by boiling the beads in 50 μl of 2×
reducing sample buffer. The GTP-agarose-bound TG2
was visualized by immunoblotting of the eluted proteins.
Western blotting and immunofluorescence
For Western blots, cells were lysed on ice in 50 mM
Tris·HCl buffer, pH 7.5, containing 150 mM NaCl and
0.5% Nonidet P-40. Fifty micrograms of total protein
from each sample were resolved on a 4% to 12% SDS
bis-tris polyacrylamide gel with running buffer and
transferred onto nitrocellulose membranes. The mem-
branes were probed with various antibodies listed in
Additional file 2. Immunofluorescent staining of cells in
monolayer and three-dimensional cultures was per-
formed as previously described [7].
RT-PCR and NF-B knockdown
The detailed procedures for RNA extraction and RT-
PCR are described in Additional file 3, and primer
sequences used for PCR are given in Additional file 4.
Quantitative RT-PCR for EMT-associated genes was
performed using the EMT-PCR Array (PAHS-090A-12;
SABiosciences/QIAGEN, Frederick, MD, USA) accord-
ing to the manufacturer’s protocol. Expression of the
p65 subunit of NF-B was knocked down using two dif-
ferent p65 siRNA sequences (Cell Signaling Technology,
Danvers, MA, USA) as previously described [6].
Cell migration, invasion, colony formation, cell viability
and NF-B activity
Invasion using a Matrigel transwell assay [6], cell viabi-
lity using an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
assay [19] and NF-B activity using an electrophoretic
mobility shift assay [20] were analyzed as previously
described. A soft agar assay also was performed as
described previously [7]. Cultures were photographed,
and the colonies with diameters larger than 500 mm
were counted.
Wound-healing assay
Cells were seeded in 12-well plates to about 70% to 80%
confluence. A 1-ml pipette tip was used to make a hori-
zontal scratch across the monolayer. Plates were washed
to remove detached cells and were replenished with
fresh medium. Wells containing scratched monolayers
were then photographed under a bright-field microscope
immediately before (0 hours) and after 6 to 8 hours’
incubation.
Mammosphere culture and differentiation
Mammosphere culture and differentiation were per-
formed as described by Dontu et al. [21] and modified
by Kumar et al. [8]. Briefly, after 7 to 10 days of culture
in methylcellulose-containing (0.9% vol/vol to prevent
cell aggregation) MammoCult medium (Stemcell Tech-
nologies, Vancouver, BC, Canada), the generated mam-
mospheres with diameters greater than 75 μm were
counted. For serial passages, mammospheres were col-
lected by gentle centrifugation (800 rpm) and disso-
ciated enzymatically (10 minutes in 0.05% trypsin
containing 0.53 mM ethylenediaminetetraacetic acid)
and mechanically using a fire-polished Pasteur pipette as
described elsewhere. For differentiation, individual mam-
mospheres were grown for 10 to 12 days in three-
dimensional Matrigel culture in the presence of prolac-
tin (2 μg/ml).
Results
Transglutaminase 2 expression in MCF10A cells
The expression of various TG2 constructs in MCF10A
cells was determined by immunoblotting (Figure 1A).
MCF10A cells transfected with wild-type TG2 (TG2-
WT) served as a positive control. All TG2 proteins, the
TG2-WT as well as the mutant TG2 lacking transami-
dation activity (TG2-C277S and TG2-W241A) or GTP-
binding activity (TG2-R580A), migrated as a single 78
kDa band. The level of TG2 expression was slightly
higher in TG2-R580A-transfected MCF10A cells than in
the TG2-C277S- or TG2-WT-transfected cells. No
detectable expression of TG2 was observed in vector-
transfected cells (Vec). In parallel with the immunoblot-
ting results, we also observed the expression of all three
forms of TG2 by immunostaining assay (Figure 1B). To
determine the transglutaminase activity of different TG2
constructs, in situ transamidation activity was deter-
mined by studying the conjugation of BPA to cellular
proteins. The calcium ionophore A23187 was used to
induce intracellular calcium and activation of TG2. As
expected, no BPA conjugation was evident in cells lack-
ing TG2 expression (Vec) or harboring catalytically inac-
tive mutant protein (TG2-C277S), whereas TG2-WT-
and TG2-R580A-transfected cells showed significant
conjugation of BPA to multiple cellular proteins. Both
the basal and A23187-induced conjugation of BPA were
much higher in TG2-R580A cells (Figure 1C). These
results suggest that TG2-R580A cells have constitutive
active transglutaminase activity due to the lack of GTP-
binding function, whereas TG2-C277S cells are deficient
in transglutamination activity even in the presence of
calcium. To determine the GTP-binding ability of differ-
ent TG2 constructs, we performed the GTP agarose
pull-down assay. We confirmed that only TG2-WT and
TG2-C277S bind to GTP-agarose (Figure 1D). As pre-
viously observed [18], the extent of GTP binding to
TG2-C277S was relatively less than to TG2-WT. TG2-
R580A failed to bind GTP agarose, even after overnight
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Figure 1 Expression and characterization of transglutaminase 2 constructs in MCF10A cells. (A) Representative immunoblot of cell lysates
showing transglutaminase 2 (TG2) expression in MCF10A sublines stably transfected with lentiviral vector alone (Vec) or lentiviral vector
containing the wild-type (TG2-WT), transamidase-inactive (TG2-C277S) or GTP-binding inactive (TG2-R580A) TG2 construct. The membrane was
stripped and reprobed with anti-actin antibody to ensure even protein loading. (B) Immunofluorescent staining for TG2 and 4’,6-diamidino-2-
phenylindole (blue) staining for the nuclei in the indicated MCF10A sublines. Original magnification ×200. (C) In situ transamidation activity of
TG2 constructs was studied by preincubating the indicated MCF10A cells with 1 mM 5-(biotinamido)pentylamine (BPA) overnight, followed by 8
hours of incubation in medium alone (-) or medium containing 8 μM (+) calcium ionophore, A23187. Cells were harvested, and BPA-conjugated
cellular proteins were detected by an immunoblotting type assay using horseradish peroxidase-conjugated streptavidin as a probe. The
membrane was reprobed with anti-TG2 and b-actin antibody to ensure even loading and levels of TG2 expression. (D) Immunoblot showing
GTP-binding ability of different TG2 constructs. Pull-down experiments were performed with GTP-agarose beads incubated for either 30 minutes
(30’) or overnight (o/n) to evaluate GTP-binding ability for the indicated TG2 forms. Input shows the level of TG2 expression in MCF10A cell lines
expressing different TG2 constructs.
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incubation. These results suggest that the GTP-binding
ability of TG2 proteins is TG2-WT > TG2-C277S >
TG2-R580A, in that order.
GTP-binding function of transglutaminase 2 is essential
for inducing mesenchymal transition
We have previously observed that neoexpression of TG2
results in induction of EMT in nontransformed
MCF10A and MCF12A mammary epithelial cells [7].
Similarly to the TG2-WT cells, TG2-C277S cells
acquired spindle-shaped morphology and exhibited scat-
tered distribution with a fibroblast-like appearance (Fig-
ure 2A). In contrast, the TG2-R580A cells appeared
similar to the control vector-transfected cells, with a
cobblestone-like epithelial appearance and tight cell-to-
cell junctions (Figure 2A). These observations suggest
that the GTP-binding activity of TG2 might be essential
for inducing EMT in MCF10A cells. To test this notion,
we next studied various EMT-related molecular altera-
tions in TG2-transfected cells. We found that TG2-
R580A cells expressed high basal levels of epithelial
marker proteins (E-cadherin and b-catenin) with mini-
mal or undetectable alterations in mesenchymal marker
proteins (fibronectin, vimentin and N-cadherin) (Figure
2B). The TG2-WT and TG2-C277S cells, in contrast,
showed almost a complete loss of E-cadherin, decreased
b-catenin and increased expression of mesenchymal
markers (N-cadherin, fibronectin and vimentin) (Figure
2B). These changes were further confirmed by immuno-
fluorescent staining. The vector-infected and TG2-
R580A cells showed distinct membranous staining for
E-cadherin and b-catenin and diminished staining for
fibronectin. In contrast, TG2-WT and TG2-C277S cells
showed no E-cadherin staining, decreased b-catenin
staining and increased fibronectin staining (Figure 2C).
Overall, these results suggest that aberrant expression of
WT or catalytically inactive (C277S) TG2 mutants is
effective in promoting the EMT and that the GTP-bind-
ing function of TG2 is critical to this effect.
GTP-binding activity of transglutaminase 2 is essential for
Snail, Twist, and Zeb expression
Induction of EMT involves complex molecular altera-
tions primarily choreographed by transcription factors
such as Snail1, Slug, Twist, Zeb1, Zeb2, E12 and E47
[2,3]. To determine the effect of TG2 mutants on tran-
scriptional regulation of EMT-associated genes, we
determined the transcriptional profile of EMT-asso-
ciated genes using a real-time PCR-based EMT array
(SABiosciences/QIAGEN). The results shown in Figure
3A demonstrate the fold change relative to the control
cells (MCF10A-vec) in EMT-associated genes in
MCF10A cells transfected with different TG2 constructs.
The results obtained revealed a several-fold decrease in
the expression of epithelial marker genes such as CDH1
(E-cadherin), KRT19 (keratin 19), BMP7 (bone morpho-
genetic protein 7) and OCLN (occludin), with concomi-
tant increases in mesenchymal marker genes such as
CDH2 (N-cadherin), VCAN (versican), FN1 (fibronectin)
and VIM (vimentin) in TG2-C277S and TG2-WT cells.
In TG2-R580A cells, a slight decrease in epithelial mar-
ker genes (KRT19, KRT14, CALD1 and OCLN) was
observed, but no change in the CDH1 gene transcript
was evident. For mesenchymal marker genes such as
CDH2, VCAN, FN1, SPARC and VIM, expression either
was unaltered or even the basal expression of these
genes was downregulated in TG2-R580A cells (Figure
3A). Overall, these results suggest that TG2-WT and
TG2-C277S cells undergo mesenchymal transition,
whereas TG2-R580A cells continue to exhibit an epithe-
lial phenotype. Moreover, the expression of transcription
repressors Snail1, Zeb1, Zeb2 and Twist1 in TG2-WT
and TG2-C277S cells was upregulated, whereas these
transcription factors were downregulated in TG2-R580A
cells. Altered expression of Snail1, Zeb1 and Twist1 in
response to WT and mutant TG2 expression was
further validated by RT-PCR (Figure 3B) and Western
blot analysis (Figure 3C). These results imply that tran-
scriptional repression of E-cadherin and upregulation of
fibronectin, N-cadherin and vimentin in MCF10A cells
in response to TG2 expression entail intact GTP-bind-
ing activity, whereas transamidation activity is not essen-
tial for inducing these changes.
GTP-binding activity of transglutaminase 2 is essential for
promoting invasiveness and drug resistance
Metastasis is a multistep process and involves increased
migration, protease secretion and altered adhesion of
cancer cells to allow their dissemination from primary
tumor sites [22]. In this context, our finding that stable
expression of TG2-WT or TG2-C277S in MCF10A cells
is associated with increased expression of the matrix
metalloproteases MMP2 and MMP3 (Figure 3A) and
transition to the mesenchymal state (Figure 2A),
whereas TG2-R580A expression results in decreased
MMP2 levels (Figure 3A) without any change in cellular
morphology, is of interest. Moreover, the TG2-C277S
cells showed increased motility in the wound-healing
assay, whereas TG2-WT and TG2-R580A cells showed
low motility, similarly to the 10A-Vec cells (Additional
file 5). To further evaluate the invasive potential, we
performed a Matrigel invasion assay and found that the
number of cells that invaded through Matrigel was sig-
nificantly higher for TG2-WT and TG2-C277S cells
than for the vector-infected or TG2-R580A cells (Figure
4A). These results further support our hypothesis that
catalytic inactive TG2 (C277S) is as effective as WT-
TG2 in inducing EMT and promoting an invasive
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Figure 2 GTP-binding activity is critical for transglutaminase 2-induced epithelial-to-mesenchymal transition. (A) Phase-contrast images
of MCF-10A cells expressing the lentiviral vector alone (Vec) or vector containing wild-type (TG2-WT) or mutant transglutaminase 2 (TG2)
constructs (TG2-C277S and TG2-R580A) were taken after 48 hours of culture in puromycin selection medium. Original magnification ×200. (B)
Immunoblot analysis of control (Vec) and TG2-expressing MCF10A cells. Expression of epithelial cell markers (E-cadherin and b-catenin) and
mesenchymal cell markers (N-cadherin, fibronectin and vimentin) was examined by immunoblotting. (C) Immunofluorescence due to expression
of epithelial-to-mesenchymal transition markers in MCF10A sublines. Cells were counterstained with 4’,6-diamidino-2-phenylindole (blue) for
nuclear staining.
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Figure 3 GTP-binding inactive transglutaminase 2 is unable to induce the epithelial-to-mesenchymal transition transcription
repressors. (A) Real-time RT-PCR array showing changes in the expression of epithelial-to-mesenchymal transition-related genes in MCF10A
sublines expressing wild-type (WT) or mutant constructs of transglutaminase 2 (TG2) relative to control lentiviral vector (Vec)-transfected MCF10A
cells. The y-axis denotes the fold change in transcript levels, the blue bars denote the gene expression in TG2-WT cells, the red bars denote
gene expression in TG2-C277S and the green bars denote gene expression in TG2-R580A cells. The expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), b-actin and 18S ribosomal RNA was used to normalize variable template loading. (B) RT-PCR analysis (RT) and (C)
Western blot analysis (WB) were performed to validate the expression of transcription factors Snail1, Zeb1 and Twist1 in different MCF10A
sublines.
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phenotype in epithelial cells, whereas GTP-binding-defi-
cient (R580A) TG2 lacked this ability.
Next we determined the effect of different TG2 forms in
conferring resistance to doxorubicin. The results shown
in Figure 4B reveal that cells expressing TG2-C277S and
TG2-WT are relatively resistant to doxorubicin-induced
killing compared with TG2-R580A or vector-transfected
cells. After that step, we determined the oncogenic
potential of three TG2 constructs by studying ancho-
rage-independent growth of cells in soft agar, an in vitro
surrogate measure for tumorigenicity [23]. We found
that catalytically inactive TG2-expressing MCF10A cells
(TG2-C277S) showed high frequency of colony forma-
tion, similar to that for TG2-WT cells, whereas GTP-
binding-defective TG2-R580A cells, similarly to the con-
trol MCF10A-Vec cells, failed to survive and form colo-
nies under these conditions (Figure 4C).
Previously, we reported that TG2 expression in
MCF10A cells disrupts their normal organization into
acinar structures when grown in three-dimensional cul-
ture [7]. We next sought to determine whether catalytic
inactive mutants (TG2-C277S) or GTP-binding-null
mutants (TG2-R580A) would have a similar effect on
acinar organization. We found that TG2-R580A cells,
similarly to vector-infected cells, formed well-organized
acinar structures (Figure 4D). These acinar structures
contained hollow lumina with laminin V staining all
around the basement layer, demonstrating apicobasal
polarization to the cells (Figure 4E). Moreover, the vec-
tor-infected and TG2-R580A cells generated acinar
spheroids that showed strong E-cadherin expression in
cells adjacent to the basal layer (Additional file 6). In
contrast, TG2-C277S and TG2-WT cells produced aci-
nar spheroids with disrupted architecture. They were
relatively larger in size without the lumen (Figure 4D).
Moreover, these structures showed diffused laminin
staining in the basement membrane (Figure 4E), and the
cells lacked E-cadherin expression (Additional file 6).
These results suggest that the GTP-binding function of
TG2 is critical for promoting cell motility, invasiveness
and anchorage-independent growth in mammary epithe-
lial cells.
GTP-binding function of transglutaminase 2 is essential
for NF-B activation
TG2 expression in normal and transformed cells is asso-
ciated with constitutive activation of NF-B [20,24], the
transcription factor that has been implicated in EMT
[25,26]. Therefore, we next sought to determine whether
failure of the TG2-R580A mutant to induce EMT is
related to its NF-B regulatory function. Our results
(Figure 5A) confirm earlier observations that TG2-WT
expression is associated with constitutive NF-B activity
in MCF10A cells. Importantly, the catalytically inactive
TG2-C277S was as effective as TG2-WT in inducing
NF-B activation, whereas the GTP-binding-null TG2-
R580A mutant was considerably less active in this
regard. To determine the significance of TG2-induced
NF-B activity in the EMT process, we knocked down
the expression of the p65 subunit of NF-B in TG2-
expressing MCF10A cells and determined various
epithelial and mesenchymal markers. The results indi-
cated that downregulation of p65 expression in TG2-
WT cells could dramatically reverse the EMT phenotype
(MET) without affecting TG2 levels (Figure 5B). Hence,
knockdown of the p65 subunit reversed the expression
of Snail1, increased the expression of the epithelial mar-
ker E-cadherin and reduced the expression of the
mesenchymal marker fibronectin without affecting TG2
expression (Figure 5B). These results establish that NF-
B activation is an important downstream mediator of
TG2-induced EMT. Similarly, other mediators, such as
activated Akt and focal adhesion kinase (FAK), which
are known to support the transition of epithelial cells to
the mesenchymal state, were also found to be activated
in TG2-expressing cells. Akt activation was selectively
observed in TG2-WT and TG2-C277S cells, however,
whereas FAK activation was evident in all three types of
TG2-expressing cells (Figure 5C).
GTP-binding activity and stem cellness
Next we studied whether the GTP-binding function of
TG2, which seems to be critical for inducting EMT, has
any effect on the acquisition of stem cell phenotype.
Analysis of the antigenic mammary stem cell surface
markers CD44 and CD24 and the ability to form mam-
mospheres suggested that, although TG2-WT [8] and its
catalytically inactive TG2-C277S mutant resulted in
enrichment of the CD44high/CD24low cell subpopulation
(Figure 6A) and increased the ability to form mammo-
spheres (Figure 6B), the GTP-defective TG2-R580A
mutant failed to do so (Figure 6). We then tested the
self-renewal capability of cells using an in vitro assay
that relies on assessing the sphere initiation efficiency of
serially passaged cells cultured as mammospheres. Once
again TG2-WT [8] and TG2-C277S were equally effi-
cient in promoting the self-renewal ability of MCF10A
mammospheres (Figure 6C). In contrast, the TG2-
R580A-expressing cells showed a progressive decrease in
the number of mammosphere-forming cells with each
passage (Figure 6D). Another important feature of stem
cells is their ability to differentiate into multiple
lineages. To determine how TG2 mutations could affect
the ability of stem cells to differentiate into secondary
structures, we transferred individual mammospheres
into Matrigel cultures. Under these culture conditions,
the mammospheres derived from either TG2-C277S- or
TG2-R580A-expressing cells differentiated and formed
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Figure 4 GTP-binding deficienttransglutaminase 2 fails to promote survival, invasion and drug resistance. (A) A transwell Matrigel
invasion assay was performed with the indicated MCF10A sublines. Cells that invaded through the Matrigel after 72 hours of incubation were
counted in five random microscopic fields. Original magnification ×20. Experiments were performed three times in triplicate. The results shown
are the average number of invading cells per field ± SEM. Vec, lentiviral vector. (B) The sensitivity of the indicated MCF10A sublines to
doxorubicin is shown. Quadruplicate wells in 96-well plates, containing 2,000 cells per well in 0.2 ml of the complete medium (10% FCS), were
either left untreated or treated with the indicated concentrations of doxorubicin. Two days after the treatment viable cells remaining in the wells
were determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reduction test, and
percentage cell viability was calculated. Experiments were repeated at least three times with similar results. Bars, mean of quadruplicate values
from a representative experiment; lines, SD. (C) Average number of colonies formed from three independent experiments ± SEM after 3 weeks
of incubation of the cells in soft agar. Images of colonies formed from a representative experiment after 3 weeks of culture in soft agar are
shown in the right panel. Original magnification ×10. (D) Phase-contrast images of acinar structures (at days 4 and 12) formed as a result of the
indicated MCF10A cells cultured in Matrigel-coated glass slide chambers for the indicated time periods. (E) Loss of basement membrane in
MCF10A sublines expressing WT- or C277S-TG2 after 12 days of culture in Matrigel-coated chambers. Structures thus obtained were
immunostained for laminin V (green) and 4’,6-diamidino-2-phenylindole (blue). Images shown are from a representative experiment repeated
twice with similar results. Original magnification ×20.
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Figure 5 Transglutaminase 2 requires a functional GTP-binding domain to activate NF-B and Akt signaling. (A) Electrophoretic mobility
shift assay for NF-B activity in the nuclear extracts prepared from the indicated MCF-10A cells. (B) Immunoblot analysis for different epithelial
and mesenchymal marker proteins in transglutaminase 2 wild-type (TG2-WT) cells before and after transfection with either control or p65-specific
siRNA. (C) Immunoblot analysis showing the levels of total and pAKT (S473) and phosphorylated focal adhesion kinase (pFAK) (Y397) in control
and TG2-transfected MCF10A sublines.
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Figure 6 GTP-binding function of transglutaminase 2 is essential for promoting the stem cell phenotype. (A) Fluorescence-activated cell
sorting analysis for the mammary stem cell antigenic markers CD44 and CD24 in MCF10A cells expressing catalytically inactive (TG2-C277S) and
GTP-binding-defective (TG2-R580A) forms of transglutaminase 2 (TG2). (B) Phase-contrast images of mammospheres formed by the indicated
MCF10A cells (upper panel). In vitro quantification of mammospheres formed by TG2-C277S- and TG2-R580A-transfected MCF-10A cells (lower
panel). The data shown are the number of mammospheres formed per 1,000 seeded cells ± SEM. (C) In vitro quantification of mammospheres
formed by TG2-C277S-expressing MCF10A cells at each serial passage (M1 to M4). (D) In vitro quantification of mammospheres formed by TG2-
R580A-transfected MCF10A cells after different serial passages (M1 to M4). The data shown are the average number of mammospheres formed
per 1,000 seeded cells ± SEM of triplicate values from a representative experiment. Note the difference in scale (600 vs 10) for (C) and (D). (E)
Phase-contrast images of differentiated mammospheres following their 12-day culture in Matrigel in the presence of prolactin. (F) The
differentiated structures were immunostained for luminal marker Muc1 (red), for basal marker CD49f/integrin a6 (green) and for nuclei with 4’,6-
diamidino-2-phenylindole (blue).
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complex secondary structures representing mammary
gland-like organotypic outgrowths (Figure 6E). Immu-
nostaining of these secondary structures revealed the
presence of both Muc1 (luminal marker)- and CD49f/
integrin a6 (basal marker)-positive cells in both the
TG2-C277S- and TG2-R580A-transfected MCF10A sec-
ondary structures (Figure 6F). These results reflect that
although the R580A mutation inhibits TG2’s ability to
induce EMT and to promote stem cellness in mammary
epithelial cells, it does not interfere with their ability to
differentiate.
Discussion
Several reports have documented elevated expression of
TG2 in multiple cancer cell types [27,28]. TG2 expres-
sion in cancer cells has been linked to drug resistance
and metastasis, the phenotypes that account for nearly
90% of cancer-related deaths [29]. These observations
clearly imply that TG2 could be an attractive therapeu-
tic target for the treatment of drug-resistant and meta-
static cancers. As a first step in this direction, we
determined the activity of TG2 that is responsible for
promoting its oncogenic functions. We employed TG2-
C277S and TG2-W241A mutants (data not shown) as
the transamidation-inactive forms and TG2-R580A
mutant as the GTP-binding-deficient form. The GTP-
binding and transamidation activities of constructs in
stably transfected MCF10A cell lines were found to be
consistent with predicted activities reported in the litera-
ture and based on the structure and function informa-
tion of TG2 [30-32].
The GTP-binding and transamidation activities of
TG2 are mechanistically mutually exclusive and are
regulated by GTP and calcium. The transamidase activ-
ity of TG2 is stimulated by calcium and inhibited by
GTP, whereas GTPase activity is inhibited by calcium
[33]. It is not clear whether under physiological condi-
tions intracellular TG2 acts as a transamidase or as a
GTPase; however, the prevailing view is that, due to
high GTP and low calcium, TG2 exists as an inactive
transamidase inside the cell, where it acts mainly as a
GTP-binding protein and converts GTP into GDP. This
view is supported by our current results, in which TG2-
WT-expressing MCF10A cells failed to show any signifi-
cant in situ activity under basal culture conditions. The
GTP-binding inactive mutant (TG2-R580A), in contrast,
showed some transamidase activity even under basal
conditions (Figure 1). The transamidating in situ activity
increased in response to calcium ionophore (A23187)
treatment in TG2-WT- and TG2-R580A-transfected
cells, but not in transamidase-inactive TG2-C277S-
expressing cells. Interestingly, the transamidation activity
of TG2 had no relevance to its ability to induce EMT-
CSC in mammary epithelial cells. Thus the catalytically
inactive TG2-C277S and TG2-W241A forms of TG2
were as effective as TG2-WT in inducing the EMT-
CSC-related changes, except for some subtle quantita-
tive differences in the levels of some inducible genes
(Figure 2). The GTP-binding-inactive R580A mutant, on
the other hand, was completely inactive in inducing the
EMT-CSC-related changes, despite its high expression
and transamidation activity. The expression of each of
the three constructs was associated with decreased
growth rates in MCF10A cells and was observed to be
Vec > C277S > WT > R580A, in that order (Additional
file 7).
TG2 has received considerable attention in recent
years for its potential role in cancer cells. There is
ample evidence supporting metastatic and drug-resistant
cancer cells’ expression of high basal levels of TG2
[5,6,11,12,14,15,17]. Our quest to understand the signifi-
cance of TG2 in cancer cells led us to some rather sur-
prising findings. We found that stable expression of
TG2 in normal and transformed mammary epithelial
cells is associated with the induction of EMT [7] and
CSC [8], the phenotypes that are closely linked with the
development of drug resistance and metastasis in cancer
cells [34,35]. These observations clearly imply that aber-
rant expression of TG2 in cancer cells could promote
drug resistance and metastasis by inducing the EMT-
CSC phenotype and hence could serve as a promising
therapeutic target for reversing chemoresistance and
inhibiting metastasis. Indeed, the observations that inhi-
bition of TG2 by siRNA, small-molecule inhibitors or
antisense RNA could render cancer cells sensitive to
chemotherapeutic drugs and inhibit their invasiveness
both in vitro and in animal models [13,14,17,24]
strongly support such a contention. Therefore, knowl-
edge of the TG2 domain and function that is essential
for promoting the EMT-CSC is foundational for the
rational design of small-molecule inhibitors that are able
to harness TG2-regulated events in cancer cells.
With this intent, we initiated studies to address
whether either or both of the two well-characterized
activities (transamidation and GTPase) of TG2 are
essential for promoting EMT-CSC in mammary epithe-
lial cells. Our findings strongly suggest that the transa-
midation activity of TG2 is not essential for promoting
the EMT-CSC. However, interference with GTP-binding
function could completely abrogate its oncogenic func-
tions. Whether the failure of the TG2-R580A mutant to
support the EMT-CSC phenotype is related to its inabil-
ity to bind and hydrolyze GTP or is a consequence of
the conformational change induced as a result of single-
amino acid substitution in position 580 remains to be
determined. Indeed, it has been suggested that the TG2-
R580A mutant acquires a more open and extended con-
formation compared with the TG2-WT form [31].
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Hence the failure of TG2-R580A to promote EMT-CSC
may be related to its altered interaction with some sig-
naling proteins rather than to its inability to bind and
hydrolyze GTP. In this context, our recent observation
that the interaction of TG2 with the inhibitor of NF-B
(IB) results in constitutive activation of NF-B (Kumar
S and Mehta K, unpublished data) is of interest. It is
likely that TG2-R580A is unable to interact effectively
with IB, owing to its extended conformation. Indeed,
the TG2-induced activation of NF-B was significantly
compromised in TG2-R580A-transfected cells compared
with the TG2-WT, TG2-C277S (Figure 5A) or TG2-
W241A cells (data not shown). Constitutive activation
of NF-B is frequently associated with advanced-stage
cancers and is known to confer resistance to chemother-
apy and to promote metastasis by inducing EMT
[36-38]. As a proof of concept, our data support the
hypothesis that TG2-induced EMT in MCF10A cells
could be reversed (MET) by inhibiting NF-B activity.
Thus downregulation of the p65 subunit of NF-B
reversed the mesenchymal phenotype to the epithelial
phenotype without any noticeable change in TG2
expression (Figure 5B). Recently, Shao et al. [25] noted
similar involvement of NF-B in TG2-induced EMT,
invasiveness and drug resistance in ovarian cancer cells.
Overall, these observations suggest that open or closed
conformation of TG2, which depends on the intracellu-
lar environment, is the major determining factor in
TG2-induced promotion of cell survival or cell death
signaling. Thus transamidase-inactive closed conforma-
tion of TG2 (due to GTP binding in the presence of low
calcium) may promote cell survival processes by serving
as a scaffold protein and mediating protein-protein
interactions. In this context, the band 4.2 protein in red
blood cells, the only catalytically inactive member of the
transglutaminase family of proteins, primarily serves as a
scaffold protein and promotes interaction with various
membrane proteins, such as ankyrin, spectrin and CD47
[39,40]. Given the structural similarities between TG2
and protein 4.2, it is tempting to speculate that the pri-
mary function of TG2 in cancer cells is to serve as a
scaffold protein rather than as an enzyme. In this capa-
city, TG2 can promote protein-protein interactions,
resulting in constitutive activation of cellular events
needed for increased cell survival and invasive function
during advanced-stage cancer.
Conclusions
Our results provide evidence that TG2 ’s aberrant
expression in drug-resistant and metastatic cancer cells
facilitates cell survival and invasive functions indepen-
dently of its transamidation activity. Recently, Colak et
al. [30] reached a similar conclusion, supporting the
notion that conformational state rather than
transamidation activity of TG2 is an important deter-
minant in cell survival signaling under glucose-
deprived conditions. These findings provide new
insights into novel oncogenic functions of TG2 and
offer promising leads for developing small-molecule
inhibitors to intervene in TG2-regulated processes and
to prevent the progression of cancer to metastatic
disease.
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Additional file 1: Protocol for lentivirus production and infection.
Additional file 2: Table 1 Antibodies used for immunofluorescence
and immunoblotting.
Additional file 3: Protocol for RNA extraction, RT-PCR and
quantitative RT-PCR.
Additional file 4: Table 2 Primers used for PCR.
Additional file 5: Supplementary Figure 1Effect of various
transglutaminase 2 constructs on cell motility. The wound-healing
assay with indicated MCF10A sublines was performed. Cell cultures were
photographed at 0 and 6 hours after wounding.
Additional file 6: Supplementary Figure 2Effect of various
transglutaminase 2 constructs on acinar structure assembly.
MCF10A cells stably transfected with indicated construct of
transglutaminase 2 (TG2) were cultured in Matrigel-coated chambers for
12 days and immunostained for E-cadherin (green), TG2 (red) and 4’,6-
diamidino-2-phenylindole (blue). Representative images from two
independent experiments with similar results are shown. Original
magnification ×20.
Additional file 7: Supplementary Figure 3Effect of various
transglutaminase 2 constructs on MCF10A cell growth. Cells (n =
2,000) expressing indicated form of transglutaminase 2 (TG2) were
cultured in quadruplicate in a 96-well plate, and the number of cells in
each well was determined after 72 hours of culture.
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